| Literature DB >> 32711561 |
Irini M Dijkhoff1, Barbara Drasler1, Bedia Begum Karakocak1, Alke Petri-Fink1, Giuseppe Valacchi2,3, Marc Eeman4, Barbara Rothen-Rutishauser5.
Abstract
BACKGROUND: Air pollution is killing close to 5 million people a year, and harming billions more. Air pollution levels remain extremely high in many parts of the world, and air pollution-associated premature deaths have been reported for urbanized areas, particularly linked to the presence of airborne nano-sized and ultrafine particles. MAIN TEXT: To date, most of the research studies did focus on the adverse effects of air pollution on the human cardiovascular and respiratory systems. Although the skin is in direct contact with air pollutants, their damaging effects on the skin are still under investigation. Epidemiological data suggested a correlation between exposure to air pollutants and aggravation of symptoms of chronic immunological skin diseases. In this study, a systematic literature review was conducted to understand the current knowledge on the effects of airborne particulate matter on human skin. It aims at providing a deeper understanding of the interactions between air pollutants and skin to further assess their potential risks for human health.Entities:
Keywords: Air pollution; Barrier dysfunction; In vitro studies; In vivo studies; Inflammation; Oxidative stress; Particulate matter; Skin; Skin models; Urban pollution
Mesh:
Substances:
Year: 2020 PMID: 32711561 PMCID: PMC7382801 DOI: 10.1186/s12989-020-00366-y
Source DB: PubMed Journal: Part Fibre Toxicol ISSN: 1743-8977 Impact factor: 9.400
Fig. 1Schematic overview of the human skin. (A) The skin consists of the epidermis and the dermis. (B) The epidermal layer consists, from top to bottom, of the stratum corneum (SC), the stratum lucidum (SL), the stratum granulosum (SG), the stratum spinosum (SS), and the stratum basale (SB). Figure adopted with permission from van Smeden et al. [22]
Review of reported effects on the barrier function, such as proliferation, differentiation, and PM penetration in varying skin models upon exposure to PM
| Model | PM type | Dose and application | Exposure time | Main findings | Ref. |
|---|---|---|---|---|---|
| Ex vivo human skin | SRM® 1649b | 2 mg/cm2, topical | 24 h | - Pyknotic nuclei. - Decreased collagen-1 protein expression. | [ |
| Pig | SRM® 1648a and 1649b | 100 μg/m2, topical | 5 d | - Decreased E-cadherin, cytokeratin, and filaggrin protein expression. | [ |
| Mice, BALB/c with disrupted barrier | PM ≤1 μm from Seoul, Korea | 8 μg/cm2, topical | 6 h and 2 w repetitive exposures, 10 times total | - Healthy barrier: PM remained in follicles. - Disrupted barrier: penetration of PM in SS. - Repeated exposure: dermal penetration of PM. | [ |
| Mice, BALB/c | SRM® 1649b | 100 μg/m2, topical | 24 h repetitive exposures, 5 d total | - Decreased filaggrin protein expression. | [ |
| Mice, HR-1 | SRM® 1650b | 100 μg/mL, topical | 7 d | - PM internalization. | [ |
| SRM® 1650b | 100 μg/mL, topical | 7 d | - Increased keratin 10 and PCNA protein expression. | [ | |
| HSE | SRM® 2975 | 200 μg/mL, systemic | 2 d repetitive exposures, 6 d total | - Decreased keratin 16, keratin 17, and Ki67 protein expression. | [ |
| ERM-CZ120 | 200 μg/mL, systemic | 48 h | - Altered morphology of epidermis. | [ | |
| HEE | Diesel PM or vapor | 0.05% (v/v), systemic | 20 d | - Decreased protein expression of cornifin A, suprabasin, and antileukoproteinase. | [ |
| CAPs, PM2.5 | 0.5 and 2.0 μg/cm2, topical | 24 and 48 h | - PM penetration in SC after 24 h. - PM penetration in deeper layers after 48 h. - No alterations in morphology. | [ | |
| CRM no. 28 | 25 mg, topical | 6 h | - - No changes in mRNA expression of | [ | |
| SRM® 1648a | 200 ppm, systemic | 96 h | - Altered morphology. - Decreased PCNA and filaggrin protein expression. | [ | |
| SRM® 1648a | 2.2, 8.9, and 17.9 μg/cm2, topical | 24 and 48 h | - Decreased cytokeratin 10, involucrin, and loricrin protein expression. - Increased barrier permeability for 17.9 μg/cm2. - Increased protein expression of aquaporin 3. | [ | |
| PM2.5 from Seoul, Korea | 50 μg/mL, topical | 24 h | - Decreased keratin-10, claudin-1, desmocollin-1, and IFN-γ protein expression. - Increased S100A7 and S100A8 protein expression. | [ | |
| PM0.3–2.5 from Benin, West-Africa | 30 μg/cm2, topical | 24 h | - Decreased loricrin protein expression. | [ | |
| PM2.5 from Xi’an, China | 50 μg/mL, systemic | 24 h repetitive exposures, 2, 4, or 6 d total | - Increased cholesterol levels. - Reduced squalene levels. | [ | |
| NHDF | SRM®2787 | 30 μg/cm2, systemic | 24 h | - PM internalization into autolysosomes. | [ |
| ERM-CZ100 | 200 μg/mL, systemic | 24 h | - Increased elastase and collagenase activity. - Increased procollagen protein expression. | [ | |
| The pre-conditioned medium of HaCaT treated with CRM no. 28 | 125 μg/mL, systemic | 30 m, 48 h post-incubation | - Increased elastase and collagenase activity. | [ | |
| NHEK | PM2.5 from Xi’an, China | 50 μg/mL, systemic | 24 h | - Top upregulated genes of transcriptomics analysis are | [ |
| Diesel PM or vapor | 0.05% (v/v), systemic | 20 d | - Decreased envoplakin, suprabasin, filaggrin, involucrin, sciellin, caspase-14, cornifin-A protein, keratin-1, and keratin-10 protein expression. | [ | |
| Diesel PM | 30 and 60 μg/mL, systemic | 24 h | - PM internalization. | [ | |
| Asian dust storm particles from Seoul, Korea | 25 μg/mL, systemic | 24 h | - Increased | [ | |
| PM ≤1 μm from Seoul, Korea | 40 μg/cm2, systemic | 24 h | - PM internalization. | [ | |
| PM2.5 from Seoul, Korea | 50 μg/mL, systemic | 2 or 4 d | - Decreased number and length of cilia. - Increased SPRR3 protein expression. - Decreased | [ | |
| SRM®2786 | 1 mg/mL, systemic | 6 h | - RNA-Seq analysis: Upregulation of | [ | |
| PM2.5 from Seoul, Korea | 25 μg/mL, systemic | 24 h | - Top upregulated genes from transcriptomics analysis are | [ | |
| HaCaT | CRM no. 28 | 125 μg/mL, systemic | 30 m, 24 h post-incubation | - Increased elastase and collagenase activity. | [ |
| SRM® 1649b | 50 μg/cm2, systemic | 24 h | - Decreased aquaporin-3 protein expression. | [ | |
| SRM® 1649b | 50 μg/cm2, systemic | 24 h | - Decreased filaggrin, repetin, involucrin, and loricrin protein expression after 24 h. | [ | |
| PM2.5 from Shanghai, China | 10–100 μg/mL, systemic | 24 h | - Increased involucrin, repetin, and filaggrin (highest dose) protein expression. - No changes in loricrin protein expression. | [ | |
| SRM® 1649b | 25 and 50 μg/cm2, systemic | 4 and 24 h | - Decreased filaggrin protein expression. | [ | |
| SRM® 1650b | 50 μg/mL, systemic | 1, 4, 8, 12, and 24 h | - PM internalization. | [ | |
| SRM® 2975 | 100 and 200 μg/mL, systemic | 24 h | - No changes in loricrin protein expression. - Increased involucrin protein expression. - Decreased keratin 16, keratin 17, and Ki67 protein expression. - Decreased BrdU incorporation. | [ | |
| CAPs, PM2.5 | 5–25 μg/mL, systemic | 1, 3, 6, and 24 h | - PM internalization. | [ |
Abbreviations: w, week; d, day; h, hour; m, minute; HSE, human skin equivalent; HEE, human epidermal equivalent; NHEK, normal human epidermal keratinocyte; SRM, standard reference material; PM, particulate matter; CAP, concentrated ambient particles; SS, stratum spinosum; ppm, parts per million; CRM, certified reference material; BrdU, 5-bromo-2′-deoxyuridine
Review of reported effects on oxidative stress in varying skin models upon exposure to PM
| Model | PM type | Dose and application | Exposure time | Main findings | Ref. |
|---|---|---|---|---|---|
| Ex vivo human skin | SRM® 1649b | 2 mg/cm2, topical | 24 h | - Lipid peroxidation. | [ |
| Mice, C-57 | Diesel PM | 4.5, 11.1 and 26.7 mg/cm2, topical | 80 h | - Increased DNA adduct formation. | [ |
| Mice, FVB/N | SRM® 1650b | 1 mg/time (PAH extracted), topical | 12 h | - Increased | [ |
| Mice, HR-1 | SRM® 1650b | 100 μg/mL, topical | 7 d | - Increased protein carbonylation and lipid peroxidation. | [ |
| SRM® 1650b | 100 μg/mL, topical | 7 d | - ER stress: upregulation protein expression of CHOP and GRP78. - Lipid peroxidation: increased expression of HNE protein. - Mitochondrial and ER swelling. - Increased protein carbonylation. - Apoptosis: increased protein expression of BAX, active caspase-3, and caspase-9, and DNA breakage. - Autophagy: increased protein expression of LC3B-II. | [ | |
| SRM® 1650b | 100 μg/mL, topical | 7 d | - Increased protein carbonylation. - Increased NOX4 protein expression. | [ | |
| HSE | SRM® 2975 | 200 μg/mL, systemic | 2 d repetitive exposure, 6 d total | - Increased protein expression of cleaved caspase-3. | [ |
| HEE | CAPs, PM2.5 | 0.5 and 2.0 μg/cm2, topical | 24 and 48 h | - Increased isoprostanes protein level. - Increased HNE protein expression. - Increased CYP1A1 protein expression. - Increased DNA fragmentation. | [ |
| CAPs, PM2.5 | 25 μg/mL, topical | 24 and 48 h | - Increased protein carbonylation. | [ | |
| PM0.3–2.5 from Benin, West-Africa | 30 μg/cm2, topical | 24 h | - Increased HNE protein expression. - Increased - Decreased | [ | |
| CRM no. 28 | 25 mg, topical | 6 h | - Upregulated mRNA expression of | [ | |
| SRM® 1975 | 5 mg/mL, topical | 48 h | - Increased level of carbonylated proteins | [ | |
| SRM® 1648a | 2.2, 8.9, and 17.9 μg/cm2, topical | 24 and 48 h | - Decreased AhR and increased NOTCH1 protein expression. | [ | |
| NHDF | SRM® 2787 | 30 μg/cm2, systemic | 24 h | - Autophagy: accumulation of LC3-II. - Mitochondrial stress: deformed mitochondria. - Increased | [ |
| ERM-CZ100 | 50–400 μg/mL, systemic | 3.3 h | - Increased levels of intracellular ROS. | [ | |
| The pre-conditioned medium of HaCaT treated with CRM no. 28 | 125 μg/mL, systemic | 30 m, 48 h post-incubation | - Increased levels of intracellular ROS. - Increased number of apoptotic bodies. | [ | |
| SRM® 1649b | 50 μg/mL, systemic | 24 h | - Increased intracellular ROS levels. - Activation of AhR (XRE activity). - Upregulation of | [ | |
| SRM® 1649b | 100–400 μg/mL, systemic | 24 h | - Nuclear translocation of AhR. - Increased mRNA expression of - Induced apoptosis. | [ | |
| NHEK | Diesel PM or vapour | 0.05% (v/v), systemic | 20 d | - Increased Nrf2 protein expression. - Mitochondrial dysfunction: overexpression of proteins from mitochondrial complex I and IV. | [ |
| SRM® 1975 | 5 mg/mL, systemic | 1 and 24 h | - Increased intracellular ROS levels. - Increased of - Nuclear translocation of AhR. | [ | |
| ERM-CZ120 | 3, 10, 30 and 100 μg/mL, systemic | 24 and 48 h | - Increased ROS levels after 24 h. - Increased | [ | |
| PM ≤1 μm from Seoul, Korea | 40 μg/cm2, systemic | 24 h | - Increased ROS production. - Inhibition of ROS inhibited cytokine secretion. | [ | |
| PM2.5 from Seoul, Korea | 25 μg/mL, systemic | 24 h | - Top upregulated genes from transcriptomics analysis are | [ | |
| PM2.5 from Xi’an, China | 50 μg/mL, systemic | 24 h | - Top upregulated genes from transcriptomics analysis are | [ | |
| Asian dust storm particles from Seoul, Korea | 25 μg/mL, systemic | 24 h | - Increased | [ | |
| Diesel PM | 30 and 60 μg/mL, systemic | 24 h | - Increased ROS production. - Increased - Increased | [ | |
| SRM® 2786 | 1 mg/mL, systemic | 6 h | - RNA-Seq analysis: Downregulation of ER stress apoptosis-related genes such as - Upregulation of | [ | |
| SRM® 1650b and 2975 | 10 and 100 μg/mL, systemic | 1 and 24 h | - Increased radical production. | [ | |
| NHEK, HaCaT, and HEK001 | SRM® 1650b | 50 μg/mL, systemic | 72 h | - Induced senescence: increased β-galactosidase activity. | [ |
| NHEK and HaCaT | SRM® 1650b | 50 μg/mL, systemic | 0.5–48 h | - Increased intracellular ROS levels. - Nuclear translocation of AhR (0.5 h). - Induced senescence: upregulation of P16INK4A and increased number of SAHF/nuclei. Decreased colony-forming ability. - Senescence is AhR dependent. - Transcriptional regulation of P16INK4A correlates with DNA demethylation: lower methylation of the P16INK4A promoter region. | [ |
| NHDF and HaCaT | SRM® 1650b | 50 μg/mL, systemic | 30 m and 24 h | - Increased levels of lipid peroxidation and protein carbonylation after 24 h. - Increased levels of superoxide anion, hydroxyl radicals, and intracellular ROS (30 m). - Increased intracellular and mitochondrial calcium levels after 24 h. - Increased protein expression of CHOP, GRP78, active caspase-3, caspase-9, PARP, and BAX after 24 h. - Downregulated protein expression of Bcl-1 and Mcl-1 after 24 h. - Increased mitochondrial permeability after 24 h. - Reduced ATP levels after 24 h. - Increased DNA degradation and the number of apoptotic bodies after 24 h. | [ |
| HaCaT | PM2.5 from Bangkok, Thailand | 100 μg/mL, systemic | 30 m | - Increased intracellular ROS levels. | [ |
| PM2.5 from Taoyuan, China | 25, 50, 100 and 200 μg/mL, systemic | 24 h | - Increased intracellular ROS levels. - Decreased SOD activity. - Increased lipid peroxidation: accumulation of MDA protein. - Induced formation of apoptotic bodies. - Induced protein expression of cytochrome c, active caspase-3, and caspase-9. - DNA damage. | [ | |
| SRM® 1648a | 50–200 ppm, systemic | 24 and 48 h | - Increased ROS production. | [ | |
| SRM® 1648a SRM® 1649b | 50 μg/cm2, systemic | 24 h | - Nuclear translocation of AhR. - Increased | [ | |
| SRM® 1649b | 50 μg/cm2, systemic | 1 h | - Increased levels of intracellular ROS. | [ | |
| SRM® 1649b | 50 μg/cm2, systemic | 2 and 24 h | - Increased cellular and mitochondrial ROS levels after 2 h. - Increased HMOX1 protein expression after 24 h. | [ | |
| SRM® 1649b | 25 and 50 μg/cm2, systemic | 4 and 24 h | - Increased ROS production. - Increased NOX activity. | [ | |
| SRM® 1649b | 25–100 μg/cm2, systemic | 4 and 24 h | - Increased NOX2 protein expression. - Increased ROS production. | [ | |
| SRM® 1649b | 25 μg/mL, systemic | 2 and 24 h | - Increased ROS production. | [ | |
| SRM® 1649b | 50 μg/cm2, systemic | 1 and 4 h | - Increased ROS production. - Increased NOX2 activity. | [ | |
| SRM® 1649b | 25 and 50 μg/cm2, systemic | 4 and 24 h | - Increased ROS production - Increased NOX activity. | [ | |
| SRM® 1649b | 100–400 μg/mL, systemic | 24 h | - Nuclear translocation of AhR. - Increased - Induced apoptosis. | [ | |
| SRM® 1650b | 50 μg/mL, systemic | 24 h | - Increased cellular and mitochondrial ROS levels and mitochondrial stress. - Increased lipid peroxidation and protein carbonylation. - Increased cleaved caspase-3 and BAX and decreased Bcl-2 protein expression. - Induced DNA damage. - Increased number of apoptotic bodies. | [ | |
| SRM® 1650b | 50 μg/mL, systemic | 1 and 24 h | - Increased intracellular ROS and superoxide anion levels. - Increased levels of protein carbonylation and lipid peroxidation after 24 h. - Induced DNA damage and apoptotic body formation. - Increased mitochondrial permeability after 24 h. - Increased BAX, active caspase-3, and PARP and decreased Bcl-2 protein expression. | [ | |
| SRM® 1650b | 50 μg/mL, systemic | 24 h | - Increased intracellular ROS and calcium levels. - Increased levels of lipid peroxidation and protein carbonylation. - DNA damage. - Increased mitochondrial ROS, calcium, and permeability. - Apoptosis: increased protein expression of ATF6, GRP78, p-IRE1, BAX, and active caspase-3 and caspase-9. Decreased protein expression of Bcl2. Increased number of apoptotic bodies. - Autophagy: autophagic lysosomes. Increased protein expression of LC3B-II and beclin-1. | [ | |
| SRM® 1650b | 50 μg/mL, systemic | 24 h | - Increased intracellular ROS and superoxide levels. - Induced NOX activity. - Increased intracellular calcium levels and mitochondrial membrane permeability. - Induced lipid peroxidation and protein carbonylation. - DNA damage. - Increased number of apoptotic bodies. | [ | |
| SRM® 1650b | 50 μg/mL, systemic | 1, 4, 8, 12, and 24 h | - Increased intracellular ROS. - Increased levels of intracellular calcium. - ER stress: Increased protein expression of CHOP, GRP78, and p-PERK. - Increased mitochondrial permeability. - DNA damage. - Increased lipid peroxidation and protein carbonylation. - Apoptosis: Increased protein expression of BAX, DNA breakage, apoptotic body formation, and increased expression of active caspase-3 and caspase-9. - Autophagy: Increased protein expression of LC3B-II. | [ | |
| SRM® 1650b | 50 μg/mL, systemic | 30 m, 1 h, and 24 h | - Increased ROS production. - Increased levels of intracellular calcium. - Induced senescence. | [ | |
| SRM® 1650b | 50 μg/mL, systemic | 24 h | - Increased ROS production. - Increased lipid peroxidation. - Increased number of apoptotic bodies. | [ | |
| SRM® 1650b and 2975 | 10 and 100 μg/mL, systemic | 1 and 24 h | - No changes in radical production. | [ | |
| SRM® 2975 | 100 and 200 μg/mL, systemic | 24 h | - Increased protein expression of cleaved caspase-3 and PARP. - Increased protein expression of BAX and p53. | [ | |
| CRM no. 28 | 125 μg/mL, systemic | 30 m, 24 h post-incubation | - Increased levels of intracellular ROS. | [ | |
| ERM-CZ120 | 100 μg/mL, systemic | 30 m | - Increased intracellular ROS production. | [ | |
| ERM-CZ120 | 25–100 μg/mL, systemic | 3 and 24 h | - Increased CYP1A1 protein expression. - Decreased AhR protein expression. - Increased LC3-II and p62 protein expression. | [ | |
| CAPs, PM2.5 | 5–25 μg/mL, systemic | 1, 3, 6, and 24 h | - Increased HNE protein adduct formation. - Increased nuclear translocation of Nrf2. - No changes in | [ |
Abbreviations: h, hour; d, day; m, minute; HSE, human skin equivalent; HEE, human epidermal equivalent; NHEK, normal human epidermal keratinocyte; SRM, standard reference material; PM, particulate matter; CAP, concentrated ambient particles; ppm, parts per million; CRM, certified reference material; ROS, reactive oxygen species; PARP, poly (ADP-ribose) polymerase; Nrf2, nuclear factor erythroid 2-related factor 2; AhR, aryl hydrocarbon receptor; LC3-II, light-chain 3 II; BIRC5, baculoviral IAP repeat containing 5; NQO1, NAD(P) H quinone dehydrogenase 1; HMOX1, heme oxygenase 1; NOX, NADPH oxygenase; HNE, 4-hydroxy-2-nonenal; ER, endoplasmic reticulum; CYP1A1, cytochrome P450 family 1 subfamily A member 1
Review of reported effects on inflammatory cascade in varying skin models upon exposure to PM
| Model | PM type | Dose and application | Exposure time | Main findings | Ref. |
|---|---|---|---|---|---|
| Ex vivo human skin | SRM® 1649b | 2 mg/cm2, topical | 24 h | - Increased MMP-1 protein expression. | [ |
| Mice, BALB/c | SRM® 1649b | 100 μg/m2, topical | 24 h repetitive exposure, 5 d total | - Increased COX2 protein expression. | [ |
| SRM® 1649b | 100 μg/cm2, topical | 24 h repetitive exposure, 5 d total | - Increased epidermal thickness. - Neutrophil infiltration. - Increased COX2 protein expression. | [ | |
| Mice, BALB/c with disrupted barrier | PM ≤1 μm from Seoul, Korea | 8 μg/cm2, topical | 6 h and 2 w repetitive exposures, 10 times in total | - Increased epidermal thickness in both skin types. - Neutrophil infiltration. - Increased mRNA expression of IL-8 functional homologs ( - Increased mRNA expression | [ |
| Mice, NC/Nga, AE model | The soluble phase of DEP. | 1 mg/time, topical | Repetitive exposure, every 1, 3, or 9 weeks in total | - Increased AE lesion formation. - Increased total IgE levels. | [ |
| Mice, HR-1 | SRM® 1650b | 100 μg/mL, topical | 7 d | - Increased epidermal thickness. | [ |
| SRM® 1650b | 100 μg/mL, topical | 7 d | - Increased epidermal thickness. | [ | |
| SRM® 1650b | 100 μg/mL, topical | 7 d | - Increased IL-1β and IL-6 protein expression. - Increased TLR5 protein expression. - Increased MyD88 protein expression. - Increased phosphorylation of p65. | [ | |
| HSE | SRM® 2975 | 200 μg/mL, systemic | Every 2 d, 6 d total | - Decreased IL-8, CXCL10, and ICAM1 protein secretion. | [ |
| HEE | CAPs, PM2.5 | 0.5 and 2.0 μg/cm2, topical | 24 and 48 h | - Nuclear translocation of p65. - Increased IL-1α protein secretion. - Increased COX2 protein expression. | [ |
| CRM no. 28 | 25 mg, topical | 6 and 24 h | - Upregulated mRNA expression of - Downregulated expression of tissue inhibitors of MMPs (2–4) after 6 h. - Induced IL-8 and MMP-1 protein secretion after 24 h. | [ | |
| PM0.3–2.5 from Benin, West-Africa | 15 and 30 μg/cm2, topical | 24 h | - Increased IL-1α and IL-8 protein secretion. - Increased MMP-1 and MMP-3 protein expression. | [ | |
| PM2.5 from Seoul, Korea | 50 μg/mL, topical | 24 h | - Increased MMP-1 protein expression. | [ | |
| SRM® 1648a | 2.2, 8.9, and 17.9 μg/cm2, topical | 24 and 48 h | - Increased IL-1α protein secretion. | [ | |
| NHDF | SRM® 1649b | 100–400 μg/mL, systemic | 24 h | - Phosphorylation of ERK and JNK. - Increased | [ |
| Diesel PM | 30 and 60 μg/mL, systemic | 24 h | - Increased | [ | |
| SRM® 1649b | 50 μg/mL, systemic | 24 h | - Increased | [ | |
| SRM® 2787 | 30 μg/cm2, systemic | 24 h | - Increased IL-6 and IL-8 protein secretion. - Increased MMP-1 and decreased procollagen and TGF-β protein secretion. - Increased - Increased | [ | |
| ERM-CZ100 | 200 μg/mL, systemic | 24 h | - Increased MMP-1, −2,-8, −9, −13 protein expression. - Nuclear translocation of p65. - Phosphorylation of ERK, JNK, and p38. | [ | |
| The pre-conditioned medium of HaCaT treated with CRM no. 28 | 125 μg/mL, systemic | 30 m, 48 h post-incubation | - Increased PGE2, TNF-α, IL-1β, and IL-6 protein secretion. - Increased COX2 protein expression. - Nuclear translocation of p65. - Phosphorylation of p38, ERK, and JNK. - Increased MMP-1 and MMP-2 protein expression. | [ | |
| Diesel PM | 30 and 60 μg/mL, systemic | 6 h | - Increased | [ | |
| NHDF and HaCaT co-culture | SRM® 1648a and SRM® 1649b | 50 μg/cm2, systemic | 24 h | - Phosphorylation of p38. - Increased - No changes in - Increased | [ |
| NHEK | PM2.5 from Xi’an, China | 50 μg/mL, systemic | 24 h | - Top upregulated genes from transcriptomics analysis are | [ |
| Diesel PM | 30 and 60 μg/mL, systemic | 24 h | - Increased | [ | |
| ERM-CZ120 | 3, 10, 30 and 100 μg/mL, systemic | 24 and 48 h | - Increased - Increased IL-1β, IL-6, IL-8, and TNF-α protein secretion after 48 h. - Increased | [ | |
| SRM® 1650b | Unknown | 24 h | - Increased IL-1β and IL6 protein secretion. - Increased IL-6 protein expression. | [ | |
| PM ≤1 μm from Seoul, Korea | 40 μg/cm2, systemic | 24 h | - Increased - Increased | [ | |
| SRM® 2786 | 1 mg/mL, systemic | 6 h | - RNA-Seq analysis: Upregulation of | [ | |
| SRM® 1649b | 50 μg/cm2, systemic | 24 h | - Increased COX2 protein expression. | [ | |
| SRM® 1649b | 100 μg/mL, systemic | 24 and 48 h | - Increased IL-8 protein secretion. | [ | |
| Diesel PM | 20 μg/mL, systemic | 48 h | - Increased IL-1β and IL-8 protein secretion. | [ | |
| Diesel PM | 30 and 60 μg/mL, systemic | 6 h | - Increased | [ | |
| Asian dust storm particles from Seoul, Korea | 25 μg/mL, systemic | 24 h | - Increased - No changes in | [ | |
| PM2.5 from Seoul, Korea | 25 μg/mL, systemic | 24 h | - Top upregulated genes from transcriptomics analysis are - Downregulated gene is - Induced IL-1α protein secretion. - Phosphorylation of p65 and p38. | [ | |
| HaCaT | CRM no. 28 | 125 μg/mL, systemic | 30 m, 48 h post-incubation | - Increased PGE2, TNF-α, IL-1β, and IL6 protein secretion. - Increased COX2 protein expression. - Nuclear translocation of p65. - Phosphorylation of p38, ERK, and JNK. - Increased MMP-1 and MMP-2 protein expression. | [ |
| PM2.5 from Shanghai, China | 10–100 μg/mL, systemic | 24 h | - No changes in CSF2 protein secretion. - Increased TSLP, TNF-α, IL-1α, and IL-8 protein secretion. | [ | |
| SRM® 1648a | 50–200 ppm, systemic | 24 and 48 h | - Increased - Increased IL-1β, IL-8, and TNF-α protein secretion. | [ | |
| SRM® 1648a and SRM® 1649b | 50 μg/cm2, systemic | 24 h | - Induced phosphorylation of p-38. | [ | |
| SRM® 1649b | 50 μg/cm2, systemic | 6 and 24 h | - Increased phosphorylation of ERK, p38, JNK, and Akt after 6 h. - Increased COX2, ICAM1, cPLA2, and PGE2 protein expression after 24 h. - Increased MMP-9 protein expression after 24 h. | [ | |
| SRM® 1649b | 50 μg/cm2, systemic | 2 and 6 h | - Increased COX2 and MMP-9 protein expression. - Phosphorylation of ERK, JNK, and p38. | [ | |
| SRM® 1649b | 25 and 50 μg/cm2, systemic | 4 and 24 h | - Increased COX2 protein expression. - Increased PGE2 and IL-6 protein secretion. - No changes in IL-24, IL-1β, and TNF-α protein secretion. | [ | |
| SRM® 1649b | 25–100 μg/cm2, systemic | 4 and 24 h | - Increased COX2 protein (24 h) and mRNA (6 h) expression. - Increased PGE2 protein secretion after 24 h. - Nuclear translocation p65 after 4 h. - Phosphorylation of ERK, JNK, and p38 after 4 h. | [ | |
| SRM® 1649b | 25 μg/mL, systemic | 2 and 24 h | - Increased IL-6, IL-1β, and IL-1α protein secretion, and mRNA expression. - Phosphorylation of p38 and AP-1. | [ | |
| SRM® 1649b | 50 μg/mL, systemic | UK | - Increased protein expression of COX2, PLA2, ICAM1, and MMP-9. - Phosphorylation of ERK, p38, and JNK. | [ | |
| SRM® 1649b | 50 μg/cm2, systemic | 6 and 24 h | - Increased COX2 protein (24 h) and mRNA (6 h) expression. - Increased PGE2 protein secretion. - Phosphorylation of p38, ERK, JNK, and p65. | [ | |
| SRM® 1649b | 100–400 μg/mL, systemic | 24 h | - Phosphorylation of ERK and JNK. - Increased | [ | |
| SRM® 1650b | Unknown | 1 h | - Binding of PM to TLR5. | [ | |
| SRM® 1650b | 50 μg/mL, systemic | 24 h | - Induced phosphorylation of ERK, p38, and JNK. | [ | |
| SRM® 1650b | Unknown | 3 h | - Increased IL-1β, IL-6, IL-8, IL-16, and TGF-β2 protein secretion. - Increased | [ | |
| SRM® 1650b | Unknown | 24–72 h | - Increased IL-1β, IL-6, IL-8, IL-16, and TGF-β2 protein secretion. - Increased IL-6 protein expression (time-dependent increase). - Increased - Increased TLR5 protein and mRNA expression. - Increased MyD88 protein expression. - Nuclear translocation of p65. - NOX4-TLR5 interaction. | [ | |
| SRM® 1650b | 50 μg/mL, systemic | 24 h | - Phosphorylation of ERK, JNK, and p38. | [ | |
| SRM® 1650b | 50 μg/mL, systemic | 30 m, 1 h, and 24 h | - Increased MMP-1 protein activity, expression, and mRNA expression. - Increased MMP-2 and MMP-9 protein expression. - Activation of the MAPK pathway. - AP-1 binding to MMP-1 promotor. | [ | |
| SRM® 2975 | 100 and 200 μg/mL, systemic | 30 m and 24 h | - Decreased IL-8 and CXCL10 protein secretion after 24 h. - Phosphorylation of p38, ERK, and JNK after 30 min. | [ | |
| CAPs, PM2.5 | 5–25 μg/mL, systemic | 1, 3, 6 and 24 h | - Nuclear translocation of p65. - Increased IL-1α protein secretion. | [ | |
| CRM no. 28 | 125 μg/mL, systemic | 30 m, 24 h post-incubation | - Nuclear translocation of p65. - Phosphorylation of p38, ERK, and JNK. - Increased PGE2, TNF-α, and IL-6 protein secretion. - Increased COX2 protein expression. | [ | |
| CRM no. 28 | 125 μg/mL, systemic | 30 m, 24 h post-incubation | - Nuclear translocation of p65. - Phosphorylation of p38. - Increased COX2 protein expression. - Increased PGE2, IL-6, TNF-α, and IL-1β protein secretion. | [ | |
| ERM-CZ100 and ERM-CZ120 | 100 μg/mL, systemic | 24 h | - Increased IL-1β, PGE2, and IL-6 protein secretion. - Increased COX2 protein expression. | [ | |
| ERM-CZ120 | 100–400 μg/mL, systemic | 24 and 48 h | - Increased PGE2 protein secretion. | [ | |
| HEK-001 | SRM® 1650b | Unknown | 24 h | - Increased IL-1β and IL-6 protein secretion. - Increased IL-6 protein expression. | [ |
| JB6 P+, mouse cell line | SRM® 1975 | 10–20 μg/mL, systemic | 12, 24, 36, and 48 h | - Activation of NF-κB. - No activation of AP-1. - Activation of the Akt/PI3K pathway. - Phosphorylation of ERK, not of p38 and JNK. | [ |
Abbreviations: h, hour; d, day; HSE, human skin equivalent; HEE, human epidermal equivalent; NHEK, normal human epidermal keratinocyte; SRM, standard reference material; PM, particulate matter; CAP, concentrated ambient particles; ppm, parts per million; CRM, certified reference material; CXCL10, C-X-C motif chemokine ligand 10; TLR, Toll-like receptor; IL, interleukin; MAPK, mitogen-activated protein kinase; TNF, tumor necrosis factor; MMP, matrix metalloprotease; NF-κB, nuclear factor kappa B; PGE2, prostaglandin E2; AP-1, adaptor protein 1
Fig. 2The main affected pathways upon exposure of the skin to airborne PM. (A) PM disrupts the barrier of skin with an already existing barrier dysfunction to a greater extent. (B) The underlying mechanism of the effects of PM exposure on the skin. PM can disrupt the epidermal barrier by increasing the levels of antimicrobial peptides (AMP) and inhibiting the levels of proteins that are essential for cell differentiation and proliferation (i.e., FLG: Filaggrin, LOR: Loricrin, KERs: Keratins). PM induces both exogenous ROS (exROS) and endogenous ROS (ROS) formation by activation of the aryl hydrocarbon receptor (AhR), upon exposure to polycyclic hydrocarbons (PAHs), and increased activity of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase enzymes (NOX). A misbalance of ROS and antioxidant scavengers results in oxidative stress. ROS activates the nuclear translocation of nuclear factor erythroid 2-related factor 2 (Nrf2) to propagate oxidative stress, by inducing the gene transcription of glutathione S-transferase (GST), heme oxygenase 1 (HMOX1), and NAD(P) H quinone dehydrogenase 1 (NQO1). ROS can cause damage to the skin by lipid peroxidation, protein carbonylation, and can cause irreversible cellular impairment through DNA damage. These damages, together with mitochondrial dysfunction, can lead to apoptosis. PM can activate the Toll-like receptor (TLR), leading to activation of the mitogen-activated protein kinase (MAPK) pathway and the nuclear factor kappa B (NF-κB) pathway. This, in turn, leads to an upregulation of gene expression of cytokines such as tumor necrosis factor (TNF), interleukin 1 alpha (IL1A), interleukin 1 beta (IL1B), as well as, chemokines such as C-X-C motif chemokine ligand 8 (CXCL8), adhesion molecules such as intercellular adhesion molecule 1 (ICAM1), enzymes such as cyclooxygenase 2 (COX2) and inducible nitric oxide synthase (iNOS), and matrix metalloproteases (MMPs). Fig. A is adapted with permission from van Smeden et al. and elements have been used for Fig. B [247]